8-K: STAAR Surgical Shareholders Approve All Proposals at 2025 Annual Meeting

STAAR Surgical Company announced that its shareholders approved the election of six directors, ratified the appointment of BDO USA, P.C. as independent auditors, and approved executive compensation on an advisory basis at its 2025 Annual Meeting.

Summary

• STAAR Surgical Company held its 2025 Annual Meeting of Shareholders on June 18, 2025.
• As of the record date, April 22, 2025, there were 49,526,129 outstanding shares of common stock.
• A quorum of 44,746,693 shares, representing approximately 90.35% of outstanding shares, was present in person or by proxy.
• Shareholders elected six directors to serve until the 2026 Annual Meeting, with strong 'For' votes ranging from 41,076,988 to 42,148,565 shares.
• The appointment of BDO USA, P.C. as the company's independent registered public accounting firm for the fiscal year ending January 2, 2026, was ratified with 44,463,071 'For' votes.
• The non-binding advisory proposal to approve the compensation of named executive officers passed with 41,130,690 'For' votes.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals were approved with strong shareholder support, indicating confidence in the company's governance, management, and auditors. There were no contentious votes or rejections.

Positives

• All three proposals presented at the 2025 Annual Meeting were approved by shareholders, indicating strong support for the company's governance and management.
• The election of all six director nominees received overwhelming shareholder approval, with 'For' votes significantly outweighing 'Withheld' votes for each candidate.
• The ratification of BDO USA, P.C. as the independent auditor passed with substantial majority, reflecting confidence in the company's financial oversight.
• The non-binding advisory vote on executive compensation also passed with a strong majority, suggesting shareholder alignment with the current compensation structure.

Future Outlook

The document does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on the outcomes of shareholder votes.

Management Comments

• Stephen C. Farrell, Chief Executive Officer, signed the report on behalf of STAAR Surgical Company.

Industry Context

This 8-K filing details the routine outcomes of an annual shareholder meeting, which is a standard corporate governance event for publicly traded companies. The results indicate stable shareholder relations and approval of standard corporate proposals, consistent with typical practices in the medical device or ophthalmic industry for established companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Exercised their voting rights on key corporate governance matters, including director elections, auditor ratification, and executive compensation.
• Management: Received shareholder approval for their compensation structure and the composition of the board, providing a clear mandate.
• Auditors (BDO USA, P.C.): Their appointment was ratified, confirming their role for the upcoming fiscal year.

Next Steps

• The elected directors will serve for a term of office expiring at the Company's 2026 Annual Meeting of Shareholders.
• BDO USA, P.C. will serve as the independent registered public accounting firm for the fiscal year ending January 2, 2026.

Key Dates

Keywords

STAAR Surgical Company, Shareholder Meeting, Annual Meeting, Corporate Governance, Director Election, Auditor Ratification, Executive Compensation, SEC Filing, 8-K, Voting Results